European Journal of Vascular & Endovascular Surgery
Volume 34, Issue 1 , Pages 10-17 , July 2007

New Antiplatelet Strategies in Atherothrombosis and Their Indications

  • P. Fontana

      Affiliations

    • Division of Angiology and Haemostasis, Department of Internal Medicine, Faculty of Medicine and University Hospitals of Geneva, Geneva, Switzerland
    • Corresponding Author InformationCorresponding author. Dr. Pierre Fontana, Division of Angiology and Haemostasis, University Medical Centre, 1 rue Michel-Servet, CH-1211 Geneva 14, Switzerland.
    • ,
  • J.-L. Reny

      Affiliations

    • Department of Internal Medicine, Centre Hospitalier de Béziers, 2 rue Valentin Hauÿ, BP 740, 34525 Béziers Cedex, France
    • Corresponding Author InformationCorresponding author. Dr. Jean-Luc Reny, Department of Internal Medicine, Centre Hospitalier de Béziers, 2 rue Valentin Hauÿ, 34525 Béziers Cedex, France.

,Accepted 18 January 2007.

References 

  1. Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol. Sep 1 2002;22(9):1381–1389
  2. Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med. Jan 14 1999;340(2):115–126
  3. Phillips DR, Conley PB, Sinha U, Andre P. Therapeutic approaches in arterial thrombosis. J Thromb Haemost. Aug 2005;3(8):1577–1589
  4. Yeh ET, Khan BV. The potential role of antiplatelet agents in modulating inflammatory markers in atherothrombosis. J Thromb Haemost. Sep 8 2006;
  5. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. Dec 1 2005;353(22):2373–2383
  6. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. Sep 2004;126(3 Suppl):234S–264S
  7. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. J Am Coll Cardiol. Dec 1988;12(6 Suppl. A):3A–13A
  8. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. Jan 12 2002;324(7329):71–86
  9. Smith SC, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. May 16 2006;113(19):2363–2372
  10. Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J. Apr 2005;26(8):804–847
  11. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. Feb 6 1992;326(6):381–386
  12. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. Jan 18 2006;295(3):306–313
  13. Hackam DG, Eikelboom JW. Antithrombotic therapy for peripheral arterial disease. Heart. Oct 11 2006;
  14. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA Guidelines for the Management of Patients with Peripheral Arterial Disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Associations for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease)–summary of recommendations. J Vasc Interv Radiol. Sep 2006;17(9):1383–1397[quiz 1398]
  15. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33(1 Suppl):S1–S75
  16. Lechat P, Priollet P. Prevention of major ischemic events in lower limb arterial disease: does aspirin play a role?. J Mal Vasc. Jul 2006;31(3):129–134
  17. Neri Serneri GG, Coccheri S, Marubini E, Violi F. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur Heart J. Oct 2004;25(20):1845–1852
  18. Savi P, Herbert JM, Pflieger AM, Dol F, Delebassee D, Combalbert J, et al. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol. Aug 4 1992;44(3):527–532
  19. Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature. Jan 11 2001;409(6817):202–207
  20. Thebault JJ, Kieffer G, Lowe GD, Nimmo WS, Cariou R. Repeated-dose pharmacodynamics of clopidogrel in healthy subjects. Semin Thromb Hemost. 1999;25(Suppl 2):9–14
  21. Cattaneo M. ADP receptors: inhibitory strategies for antiplatelet therapy. Drug News Perspect. Jun 2006;19(5):253–259
  22. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation. Apr 26 2005;111(16):2099–2106
  23. Cuisset T, Frere C, Quilici J, Morange PE, Nait-Saidi L, Carvajal J, et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol. Oct 3 2006;48(7):1339–1345
  24. Montalescot G, Sideris G, Meuleman C, Bal-dit-Sollier C, Lellouche N, Steg PG, et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol. Sep 5 2006;48(5):931–938
  25. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. Nov 16 1996;348(9038):1329–1339
  26. Hirsh J, Bhatt DL. Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies. Arch Intern Med. Oct 25 2004;164(19):2106–2110
  27. Rothwell PM. Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet. Jan 8-14 2005;365(9454):176–186
  28. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. Aug 16 2001;345(7):494–502
  29. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. Mar 24 2005;352(12):1179–1189
  30. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. Nov 5 2005;366(9497):1607–1621
  31. Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. Apr 25 1996;334(17):1084–1089
  32. Urban P, Macaya C, Rupprecht HJ, Kiemeneij F, Emanuelsson H, Fontanelli A, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation. Nov 17 1998;98(20):2126–2132
  33. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. Dec 3 1998;339(23):1665–1671
  34. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. Aug 18 2001;358(9281):527–533
  35. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. May 4 2005;293(17):2126–2130
  36. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. Jul 24 2004;364(9431):331–337
  37. Jamieson DG, Parekh A, Ezekowitz MD. Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents. J Cardiovasc Pharmacol Ther. Sep 2005;10(3):153–161
  38. Lastilla M. Lacunar infarct. Clin Exp Hypertens. Apr-May 2006;28(3-4):205–215
  39. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. Apr 20 2006;354(16):1706–1717
  40. Pfeffer MA, Jarcho JA. The charisma of subgroups and the subgroups of CHARISMA. N Engl J Med. Apr 20 2006;354(16):1744–1746
  41. Ahrens I, Bode C, Peter K. Inhibition of platelet activation and aggregation. Handb Exp Pharmacol. 2005;(170):443–462
  42. Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group. Circulation. Sep 1980;62(3):449–461
  43. Schaefer WM, Koch KC, Nowak B, Noth J, Buell U, Weiss PH. Dipyridamole/aspirin combination in secondary stroke prevention: effects on absolute myocardial blood flow and coronary vascular resistance. Int J Clin Pharmacol Ther. Jul 2006;44(7):319–325
  44. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet. May 20 2006;367(9523):1665–1673
  45. Douglas JS, Holmes DR, Kereiakes DJ, Grines CL, Block E, Ghazzal ZM, et al. Coronary stent restenosis in patients treated with cilostazol. Circulation. Nov 1 2005;112(18):2826–2832
  46. Thompson PD, Zimet R, Forbes WP, Zhang P. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol. Dec 15 2002;90(12):1314–1319
  47. Chew DP, Bhatt DL, Sapp S, Topol EJ. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation. Jan 16 2001;103(2):201–206
  48. Kastrati A, Mehilli J, Neumann FJ, Dotzer F, ten Berg J, Bollwein H, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA. Apr 5 2006;295(13):1531–1538
  49. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized phase 2 trial. Stroke. Apr 2005;36(4):880–890
  50. Ciccone A, Abraha I, Santilli I. Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke. Cochrane Database Syst Rev. 2006;(4):CD005208
  51. Gachet C. The platelet P2 receptors as molecular targets for old and new antiplatelet drugs. Pharmacol Ther. Nov 2005;108(2):180–192
  52. Gaussem P, Reny JL, Thalamas C, Chatelain N, Kroumova M, Jude B, et al. The specific thromboxane receptor antagonist S18886: pharmacokinetic and pharmacodynamic studies. J Thromb Haemost. Jul 2005;3(7):1437–1445
  53. Brass LF, Zhu L, Stalker TJ. Minding the gaps to promote thrombus growth and stability. J Clin Invest. Dec 2005;115(12):3385–3392
  54. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart. Dec 2005;91(Suppl 5):v1–v52
  55. Toni D, Chamorro A, Kaste M, Lees K, Wahlgren NG, Hacke W. Acute treatment of ischaemic stroke. European Stroke Initiative. Cerebrovasc Dis. 2004;17(Suppl 2):30–46
  56. Patrono C, Bachmann F, Baigent C, Bode C, De Caterina R, Charbonnier B, et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J. Jan 2004;25(2):166–181
  57. Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke. Feb 2006;37(2):577–617
  58. Smith SC, Feldman TE, Hirshfeld JW, Jacobs AK, Kern MJ, King SB, et al. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention–summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation. Jan 3 2006;113(1):156–175

 One of a series of educational articles edited by Janet Powell, UK.

PII: S1078-5884(07)00060-3

doi: 10.1016/j.ejvs.2007.01.004

European Journal of Vascular & Endovascular Surgery
Volume 34, Issue 1 , Pages 10-17 , July 2007

Article Tools

* Image Usage & Resolution